1. Scrip
  3. >>Alimentary/Metabolic

Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue

 
• By Emily Hayes

Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.

Plastic Autoinjector_222700717_1200.jpg
Currently, rescue treatments for severe hypoglycemia need to be reconstituted, but prefilled syringes in autoinjectors may be on the way.

Positive Phase III results across the board for Zealand Pharma AS's dasiglucagon as a ready-to-use prefilled syringe rescue medication for severe hypoclyemia put the drug on track for a US FDA filing in the second half of 2019, but far behind two competing products that are already under review – Eli Lilly & Co.'s needle-free nasal product AMG504-1 and Xeris Pharmaceuticals Inc.'s XeriSol glucagon autoinjector.

Dasiglucagon (glucagon analog stable in liquid formulation) will be delivered in Zealand's ready-to-use HypoPal autoinjector rescue pen. Severe hypoglycemia is...

More from Alimentary/Metabolic

More from Therapy Areas

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 
• By Andrew McConaghie

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.